Clinical Trials · NCT04596631

A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes

CompletedPhase 3Semaglutide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Novo Nordisk A/S
Enrollment
132
Start date
Nov 2020
Locations
97 sites, 22 countries
Primary endpoint
Change From Baseline (Week 0) to Week 26 in Glycosylated Haemoglobin (HbA1c)- Percentage Point
View Semaglutide compound reference